Back to CVE records
High 8.0Published Sep 26, 2026

CVE-2026-100561OpenClaw before 2026.8.1 Authentication Bypass via Exec Wrapper

Updated under an hour ago ()

Does this affect you?

It affects OpenClaw. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

OpenClaw (npm package 'openclaw') versions >= 2026.3.22 and < 2026.8.1 contain an approval-bypass flaw in the exec approval policy: the policy could trust a command-running wrapper without inspecting the command carried in its arguments. After an operator allowlisted or permanently approved a benign wrapper invocation, a later agent turn could substitute an arbitrary inner command and execute it with the OpenClaw process's host privileges without a further approval prompt. Exploitation requires the relevant wrapper to resolve on the host and a prior operator decision allowing that wrapper. Transparent shell carriers and opaque utilities such as process monitors, tracers, namespace tools, and proxy wrappers were affected through related trust-resolution gaps. Fixed in 2026.8.1.

CVSS
8.0 HIGH (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-88
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
VulnCheck
NVD analysis
Deferred
Record last updated
Sep 29, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
OpenClaw OpenClaw
openclaw:openclaw (from the name)
from 2026.3.22 before 2026.8.1; 2026.8.1 not affected
CNA record

References

  • vendor-advisory
  • third-party-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.